Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1994 1
1995 1
1996 1
1997 1
1998 2
2000 1
2002 1
2003 4
2004 3
2005 3
2006 3
2007 4
2008 1
2009 1
2010 1
2011 3
2012 5
2013 4
2014 5
2015 2
2016 8
2017 8
2018 4
2019 4
2020 2
2021 11
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

73 results
Results by year
Filters applied: . Clear all
Page 1
Immunogenicity of pembrolizumab in patients with advanced tumors.
van Vugt MJH, Stone JA, De Greef RHJMM, Snyder ES, Lipka L, Turner DC, Chain A, Lala M, Li M, Robey SH, Kondic AG, De Alwis D, Mayawala K, Jain L, Freshwater T. van Vugt MJH, et al. Among authors: de alwis d. J Immunother Cancer. 2019 Aug 8;7(1):212. doi: 10.1186/s40425-019-0663-4. J Immunother Cancer. 2019. PMID: 31395089 Free PMC article.
Mechanistic Basis for Maximally Efficacious Dose of Pembrolizumab.
Mayawala K, Nayak T, Jain L, de Alwis D. Mayawala K, et al. Among authors: de alwis d. Clin Pharmacol Ther. 2021 Dec 3. doi: 10.1002/cpt.2492. Online ahead of print. Clin Pharmacol Ther. 2021. PMID: 34859427 No abstract available.
Implementation of quantitative and systems pharmacology in large pharma.
Visser SA, de Alwis DP, Kerbusch T, Stone JA, Allerheiligen SR. Visser SA, et al. Among authors: de alwis dp. CPT Pharmacometrics Syst Pharmacol. 2014 Oct 22;3(10):e142. doi: 10.1038/psp.2014.40. CPT Pharmacometrics Syst Pharmacol. 2014. PMID: 25338195 Free PMC article. Review.
Pivotal Dose of Pembrolizumab: A Dose-Finding Strategy for Immuno-Oncology.
Li TR, Chatterjee M, Lala M, Abraham AK, Freshwater T, Jain L, Sinha V, de Alwis DP, Mayawala K. Li TR, et al. Among authors: de alwis dp. Clin Pharmacol Ther. 2021 Jul;110(1):200-209. doi: 10.1002/cpt.2170. Epub 2021 Mar 8. Clin Pharmacol Ther. 2021. PMID: 33462831
73 results